Molecular Targeting Technologies, Inc.

West Chester,  PA 
United States
http://www.mtarget.com
  • Booth: 934


Translating radiopharmaceuticals into tomorrow’s medicine

Molecular Targeting Technologies, Inc. (MTTI), a privately held company, focuses on radiopharmaceuticals for treatment and diagnosis of rare diseases.

Our therapeutics, supported by published data and ongoing Phase I clinical trials,  include:

  • EBTATE (177Lu-EB-DOTA-TATE), a neuroendocrine tumor therapy (NET). EBTATE shows several-fold increase of blood half-life and enhanced tumor uptake over existing PRRTs. Treatments using either 1.85 or 3.7 GBq EBTATE in NET patients were well tolerated and more
  • 131I-SapC-DOPS, a nanovesicle for glioblastoma multiforme (GBM), readily crosses the blood brain barrier delivering a dual killing effect. Preclinical studies demonstrated that the 131I-SapC-DOPS improves survival by 43% compared with SapC-DOPS alone.

Our diagnostics include:

  • TDURA (99mTc-duramycin), for systemic inflammatory response syndrome (SIRS) and organ transplant rejection applications. A clinical study for early detection of tumor response to treatment will begin in 4Q 2019.
  • 18F-glucaric acid is being developed for detecting stroke and acute MI.  99mTc-glucarate, was effective for MI detection in a phase II clinical trial.

Brands: EBTATE ( Lu-177-EB-TATE); TDURA (Tc-99m Duramycin); FGA ( F-18 glucaric acid); I-131-SapC-DOPS


 Press Releases

  • West Chester, PA, June 18, 2019  Molecular Targeting Technologies, Inc. (MTTI) announced today that it will begin Phase 0/I clinical trials of TDURA at the University of Antwerp,  MICA (Molecular Imaging Center Antwerp)  later this year, fully funded by a Phase 2 SBIR grant from the NIH National Cancer Institute.  TDURA  (99mTc-duramycin) is a SPECT imaging agent with a unique mechanism to "see" cell death. It is fast, sensitive and enables early, actionable tracking of cell damage, reducing adverse events, improving outcomes and cutting healthcare costs.

    In late 2017, early-stage investors applauded MTTI’s TDURA as a game changer in  precision medicine when it was awarded Second Prize in the Life Science Nation “RESI (Redefining Early Stage Investment) Boston 2017” investment competition for early-stage life science companies.

    Extensive preclinical work in multiple animal models  proved TDURA was safe and effective in visualizing solid colorectal tumor response to chemotherapy, distinguishing responders from non-responders as early as 1-day post-chemotherapy.  The Antwerp team and MTTI were awarded the Image of the Year by MI Labs for this work at the 2017 World Molecular Imaging Congress.

    In parallel preclinical studies, TDURA  also detected chemotherapy related cardiac dysfunction, Systemic Inflammatory Response Syndrome (SIRS), cardiac transplant rejection, plaque and acute myocardial infarction, all much earlier than current technologies.

     “TDURA is a transformational platform for  precision medicine.   We thank NCI and firmly believe that our clinical trials will justify the confidence shown by MI Labs and RESI  ” said Chris Pak, President & CEO of MTTI.

    Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.  More information: www.mtarget.com  .

    Contact: Chris Pak, Email: cpak@mtarget.com; Tel: (610) 738-7938.

  • KEY MTTI ASSETS IN DEVELOPMENT – SNMMI June 2019

    NAME: EBTATE (177Lu-DOTA-EB-TATE)

    CLASS: Therapeutic

    INDICATION:  Neuroendocrine Neoplasms (NEN)

    USE: First-in-human studies  demonstrated remarkably higher uptake and retention in neuroendocrine neoplasms  than Lutathera®.  A single low-dose EBTATE treatment appears to be safe and effective in the treatment of NEN. EBTATE may  be effective with fewer, significantly lower doses than Lutathera®.   The best EBTATE patient population includes metastatic, SSTR-positive NET patients.

    TECHNOLOGY:  EBTATE is a peptide receptor radionuclide therapy (PRRT) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.  The drug binds to and destroys somatostatin receptor expressing NET cells.  80% of NETs overexpress somatostatin receptors (particularly SSTR2)  .

    EBTATE was designed to overcome rapid clearing of Lutathera ® by chemically incorporating  an Evans Blue moiety  in its backbone.  By increasing residence in albumin,  EBTATE substantially lengthens the in vivo  half-life, increasing the probability of  binding between drug and target.  That enables fewer, lower doses of the radiotherapeutic.

    UNMET NEED:  SSAs (Somatostatin Analogs) like Sandostatin, Somatuline and Lutathera that bind to somatostatin receptors have been used to treat NETs.  All have limitations.

    PROOF OF CONCEPT: Extensive preclinical and two Phase I studies (targeting 50 patients) at Peking Union Medical College Hospital(China).

    STAGE OF DEVELOPMENT:

    ·         GLP preclinical, analytical, stability and process development through 2019.  

    ·         Phase I trial in US beginning Spring 2020.

    ·         Phase II Trial planned Sep 2021

    PRINCIPAL COLLABORATORS: NIH & Memorial Sloan Kettering Medical Center

    IP: “Chemical Conjugates of Evans Blue Derivatives and their use as Radiotherapy and Imaging Agents (PCT/US2017/054863) filed October 3, 2017, pending

    FUNDING: Applied for Fast Track Phase 1 &2 SBIR. 

    OWNERSHIP: MTTI awarded world-wide-exclusive rights by NIH 10/8/2018.


    NAME: TDURA

    CLASS: Imaging Agent

    INDICATIONS:  cancer, drug toxicity,...

    USES: demonstrated in multiple preclinical studies visualizing:

    • Tumor response to chemotherapy
    • Systemic inflammatory response syndrome (SIRS)
    • Injury due to drug toxicity
    • Organ transplant rejection
    • Atherosclerotic plaque
    • Acute myocardial infarction

    TECHNOLOGY:  Cell death is the surrogate endpoint for most disease states and anticancer therapies (tumor death).  There is no direct cell death imaging agent yet accepted in routine clinical practice.

    TDURA, a small, peptide-based radiopharmaceutical imaging agent labeled with 99mTc, sees cell death, in vivo, directly.  It enables early, actionable efficacy tracking of tumor cell death within days of the first treatment. It has a unique mechanism of action, binds well to markers on dying cells, and clears readily, a model imaging agent.

    UNMET NEED: 

    Lack of response to therapy is a major hurdle for cancer treatment. Early tracking  of tumor response to therapy is critical.  Current methods to measure tumor response observe tumor shrinkage or metabolic changes, which may not be detectable for weeks. Ending ineffective therapy early minimizes costs and patient stress.

    Systemic inflammatory response syndrome (SIRS) is associated with the presence of pro- and anti-inflammatory cytokines in serum, including tumor necrosis factor (TNF). TNF has multiple effects and leads to cytokine production, leukocyte infiltration, blood pressure reduction and coagulation, contributing to tissue damage and organ failure. TDURA imaging can be used for whole body assessment of tissue damage due to inflammation and injury.

    PROOF OF CONCEPT: 35 publications prove concept and demonstrate utility in multiple indications (see above).  Concentrated on visualizing tumor death in colorectal cancer.

    STAGE OF DEVELOPMENT: Phase 0/1 development at Univ of Antwerp in Q4 2019.  

    PRINCIPAL COLLABORATOR: University of Antwerp MICA (Molecular Imaging Center Antwerp)

    IP: US 7,877,783 B2, US 8,778,303B2, Chinese patent CN102014970B, European approved 2017. These patents are secure through 2029 in US, EU and China. MTTI obtained an exclusive license from the Medical College of Wisconsin.

    FUNDING: ~$3 million non-dilutive grants from NIH & EU.

    OWNERSHIP: MTTI


    NAME: 131I SapC-DOPS 

    CLASS: Therapeutic Agent

    INDICATION: glioblastoma multiforme (brain cancer)

    USE:  Targeted radio- and biotherapy of glioblastoma multiforme.

    TECHNOLOGY:  SapC-DOPS, a nanovesicle composed of saposin C (SapC)  polypeptide and dioleoylphosphatidylserine (DOPS), has proven tumor targeting properties (crossing the blood-brain and blood-tumor barriers, then binding a lipid tumor marker, extracellular phosphatidylserine(PS)). It shows antitumor activities in preclinical glioblastoma (GBM) models.

    Incorporating  a radiotherapeutic iodine in the  SapC-DOPS nanovesicle provides a novel agent with potentially superior efficacy for targeted radionuclide therapy (TRT) of glioblastomas (GBMs).  NIH NCI funded Proof of Concept studies demonstrate a 43% increase in mouse survival over a non-radioactive nanovesicles.

    UNMET NEED: GBM is among the most aggressive and intractable cancers. Current average survival is <2 years. Treatment options are limited. Standard therapies with surgery, radiation and/or chemotherapy provide modest survival improvement.  Frequent, severe side effects from surgery and subsequent therapy  seriously impact Quality of Life. Micrometastatic spread of tumor cells and residual disease are common, demanding further treatment.

    PROOF OF CONCEPT: Backed by extensive, published and unpublished, preliminary data, an FDA Orphan Drug designation and an ongoing Phase I clinical trial of non-radioactive SapC-DOPS by Bexion Pharmaceuticals, Inc.  An MTTI collaborator at the Univ. of Cincinnati has shown:

    • 127I SapC-DOPS -CVM targets GBM
    • 125I SapC-DOPS -CVM selectively accumulates in GBM
    • 131I SapC-DOPS increases survival 43% over 127I SapC-DOPS

    STAGE OF DEVELOPMENT: Preclinical. GBM drugs benefit from accelerated clinical development (GBM Agile) , Orphan designation and speedy FDA approval after Phase II trials.

    PRINCIPAL COLLABORATOR: University of Cincinnati                        

    IP: pending

    FUNDING $349,989 funding from NCI. Fast track Phase I/II SBIR application submitted.

  • Philadelphia, PA, April 23, 2019 – EY today announced that Chris Pak, Founder and CEO of Molecular Targeting Technologies, Inc. (West Chester, PA) is a finalist for the Entrepreneur Of The Year® 2019 Award in Greater Philadelphia.

    Widely considered one of the most prestigious business awards programs in the U.S., the program recognizes entrepreneurs and leaders of high-growth companies who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities, while also transforming our world. Chris was selected as a finalist by a panel of independent judges. Award winners will be announced at a special gala event on June 19, 2019 at the Kimmel Center for the Performing Arts. 

    Chris Pak said, “I’m thrilled to be recognized among this select group of  talented regional business creators.  I am honored and humbled to join these unstoppable entrepreneurs.”

    Now in its 33rd year, the program has expanded to recognize business leaders in more than 145 cities and more than 60 countries throughout the world. 

    Regional award winners are eligible for consideration for the Entrepreneur Of The Year National competition. Award winners in several national categories, as well as the Entrepreneur Of The Year National Overall Award winner, will be announced at the Entrepreneur Of The Year National Awards gala in Palm Springs, California, on November 16, 2019. The awards are the culminating event of the Strategic Growth Forum®, the nation’s most prestigious gathering of high-growth, market-leading companies.

    Sponsors

    Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards are nationally sponsored by SAP America and the Ewing Marion Kauffman Foundation.

    In Greater Philadelphia, sponsors also include PNC Bank, Donnelley Financial Solutions, Murray Devine & Company, SolomonEdwards Group, Ballard Spahr LLP, Morgan, Lewis & Bockius LLP, Pepper Hamilton LLP and Simkiss & Block.

    About Entrepreneur Of The Year®

    Entrepreneur Of The Year®, founded by EY, is the world’s most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities and more than 60 countries. ey.com/eoy

    About EY’s Growth Markets Network

    EY’s worldwide Growth Markets Network is dedicated to serving the changing needs of high-growth companies. For more than 30 years, we’ve helped many of the world’s most dynamic and ambitious companies grow into market leaders. Whether working with international mid-cap companies or early stage, venture-backed businesses, our professionals draw upon their extensive experience, insight and global resources to help your business succeed. For more information, please visit us at ey.com/gm or follow news on Twitter @EY_Growth.

    About EY

    EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation is available via ey.com/privacy. For more information about our organization, please visit ey.com.

    About MTTI

    Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.  More information: www.mtarget.com.

    Contact: Chris Pak, Email: cpak@mtarget.com; Tel: (610) 738-7938.

    This news release has been issued by Ernst & Young LLP, a member of the global EY organization that provides services to clients in the US.

    For more information, please visit ey.com.

  •                                                                                                                        

    FOR IMMEDIATE RELEASE

    Early Studies Show EBTATE is Well Tolerated and Effective in Treating Neuroendocrine Tumors

    West Chester, PA, June 18, 2019-- Molecular Targeting Technologies, Inc. (MTTI) announced today that Professor Zhaohui Zhu et. al. of the Department of Nuclear Medicine, Peking Union Medical College Hospital (PUMC), Beijing, China will present “Safety and Response of an Evans Blue-modified 177Lu-labeled Octreotate in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study” at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Anaheim this June.

    MTTI received an exclusive worldwide patent commercialization license from NIH for the Evans Blue technology. This patent estate covers 77Lu-DOTA-EB-TATE (EBTATE) radiotherapeutic. Neuroendocrine Neoplasm (NEN) treatment is among potential uses.

    The talk describes results of a dose escalation study comparing MTTI’s EBTATE to Lutathera® (177Lu-DOTATATE).  EBTATE was designed to prolong circulation half-life and increase neuroendocrine  tumor accumulation versus its predecessor.   Dr. Zhu’s team studied 26 patients in three groups with metastatic neuroendocrine tumors (NET), comparing two dose levels of EBTATE to Lutathera® against CTC (Common Toxicity Criteria) for tolerability and 68Ga-DOTA-TATE PET SUVmax for tumor response.

    Qingxing Liu and Zhaohui Zhu highlighted, “One treatment cycle of EBTATE [1.85 GBq (50 mCi) or 3.70 GBq (100 mCi) of 177Lu-DOTA-EB-TATE] seems to be well tolerated and more effective than 3.7 GBq (100 mCi) of Lutathera®. ”

     “Based on this early work, EBTATE could be the next, more effective, innovation in radiolabeled Octreotate for NET.  We’re excited about this breakthrough and thank Dr. Zhu and his colleagues for their exceptional contribution in our concerted effort to develop this robust molecule.” said Chris Pak, President & CEO of MTTI.

    Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.  More information: www.mtarget.com.

    Contact: Chris Pak, Email: cpak@mtarget.com; Tel: (610) 738-7938.

    Oral presentation:

    Safety and Response of an Evans Blue-modified 177Lu-labeled Octreotate in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Anaheim this June. By Qingxin Liu, Yuejuan Cheng, Hao Wang, Jie Zang, Jinam Wang, Orit Jacobson, Zhaohui Zhu and Xiaoyuan Chen.

    Response evaluation Group

    Response

                            CR

                        PR

                 SD

            PD

    100mCi TATE

    0

    16.7% (1/6)

    50% (3/6)

    33.3% (2/6)

    50mCi EBTATE

    0

    50% (3/6)

    50% (3/6)

    0

    100mCi EBTATE

    0

    50% (7/14)

    42.9% (6/14)

    7.1% (1/14)

    TATE: 177Lu-DOTATATE (Lutathera®); EBTATE: 177Lu-DOTA-EB-TATE (EBTATE) ;

    CR: Complete response; PR: partial response; SD: stable disease; PD: progressive disease

    Partial Remission of Bone and Lymph Node Metastases After One Cycle of   177Lu-DOTA-EBTATE (PRRT-peptide receptor radionuclide therapy).

  • FOR IMMEDIATE RELEASE

    Molecular Targeting Technologies, Inc. Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting

    West Chester, PA, June 17, 2019 -- Molecular Targeting Technologies, Inc. (MTTI)  is an oncology company creating  innovative products to see and treat cancer. MTTI’s prime platforms are EBTATE (177Lu-DOTA-EB-TATE) to treat Neuroendocrine Neoplasms (NENs) and a precision cell death targeting technology TDURA/TCP. 

    MTTI announced today that three abstracts highlighting these platforms were selected for oral and poster presentations at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting, June 22 – June 25, 2019 in Anaheim, California. MTTI  will showcase its technology in booth #934,  June 22-25, 2019 at SNMMI.

    Details on the presentations :

    Labeling Strategies of 18F-duramycin for imaging cell apoptosis

    Date & Time: Sunday, June 23, 2019 from 1:30 ­ 2:00 pm, Pacific Time 

    Oral Presentation-Session Title: Basic Science

    Abstract No.: 1750 

     

    Comparative evaluation of TCP-1 molecular probes in colorectal and pancreatic cancer model

    Date & Time: Sunday, June 23, 2019 from 6:30 ­ 8:00 pm, Pacific Time

    Poster Session Title: Preclinical Probes for Oncology Posters

    Abstract No.: 1046 

     

    Safety and Response of an Evans Blue-modified 177Lu-labeled Octreotate in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study

    Date & Time: Tuesday, June 25, 2019 from 3:00 to 4:30 pm, Pacific Time

    Oral Presentation- Session 77 Title: Translational Image Guided

    Abstract No.: 659

     

    MTTI  will showcase its technology in booth #934,  June 22-25, 2019 at SNMMI.

    EBTATE (177Lu-DOTA-EB-TATE) Innovative science overcomes rapid clearance of the market leader in neuroendocrine neoplasm treatment.  Incorporating Evans Blue (EB), an albumin binding agent, endows  EBTATE with a substantially longer half-life, enabling much smaller, less frequent dosing of the radiotherapy to deliver  the same therapeutic benefit.

    TDURA ( 99mTc-duramycin)  and FGA  (18F- glucaric acid) see apoptosis and necrosis respectively.  Both visualize response to treatment of cancers shortly after onset of the therapy, reducing patient stress, cutting costs and improving outcomes.  Both have demonstrated utility in imaging cardiac, inflammatory and pulmonary diseases.

    MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of disease. 

    More information: www.mtarget.com 

    Contact: Chris Pak, Email: cpak@mtarget.com ; Tel: (610) 738-7938

  • FOR IMMEDIATE RELEASE

    18F-Duramycin Shows Promise in Apoptosis Imaging. 

    West Chester, PA, June 18, 2019  Molecular Targeting Technologies, Inc. (MTTI) announced today that  Dr. Junling Li,  et. al. of the Department of Radiology, University of Louisville, School of Medicine, Louisville, KY will present “Labeling strategies of 18F-duramycin for imaging cell apoptosis.” at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Anaheim this June. 

    Duramycin is a small peptide that binds to PE (phosphatidylethanolamine biomarker) on dead and dying cells. Since it is small, it distributes and clears quickly.  In vivo Imaging of apoptosis using radiotracers attached to duramycin  tracks tumor response to chemotherapy within one day of starting therapy. MTTI’s TDURA (99mTc-duramycin) has been used successfully to track drug response in mice with colorectal cancer.  TDURA will enter Phase 0/1 clinical trials in late 2019.

    An  18F radiolabel may have advantages over 99mTc.  Dr Li’s team assessed three different 18F-labeling tools to derivatize duramycin on in vitro cell uptake of 18F-duramycin for imaging apoptosis.  Although all three showed good uptake and differentiation in detecting apoptosis, 18F-NODA-Duramycin was best.

    Chris Pak, President & CEO of MTTI said, “This early result shows great promise to grow our portfolio of apoptosis and necrosis diagnostic platforms.  In addition to TDURA we’re also excited about our newest 18F-Glucaric Acid which is simple to  manufacture and  performs even better than 99mTc-Glucaric Acid which we took through clinical trials several years ago”.

    Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.  More information: www.mtarget.com.

    Contact: Chris Pak, Email: cpak@mtarget.com; Tel: (610) 738-7938.


 Products

  • 131I SapC-DOPS
    Incorporating a radioiodine in a SapC-DOPS nanovesicle provides a novel agent for targeted radionuclide therapy (TRT) of glioblastomas . Proof of Concept studies demonstrate a 43% increase in mouse survival over a non-radioactive nanovesicles....

  • INDICATION: glioblastoma multiforme (brain cancer)

    USE:  Targeted radio- and biotherapy of glioblastoma multiforme

    STAGE OF DEVELOPMENT: Preclinical. GBM drugs benefit from accelerated clinical development (GBM Agile) , Orphan designation and speedy FDA approval after Phase II trials.

    PRINCIPAL COLLABORATOR: University of Cincinnati                        

    IP: pending

    FUNDING $349,989 funding from NCI. Fast track Phase I/II SBIR application submitted.

  • EBTATE (177Lu-DOTA-EB-TATE)
    EBTATE is a peptide receptor radionuclide therapy for neuroendocrine tumors. In First-in-Human studies, a single low-dose EBTATE treatment appears to be safe and effective with fewer, significantly lower doses than Lutathera®....

  • CLASS: Therapeutic

    NAME: 177Lu-DOTA-EB-TATE (EBTATE)

    INDICATION:  Neuroendocrine Neoplasms (NEN)

    PROOF OF CONCEPT: Extensive preclinical and two Phase I studies (targeting 50 patients) at Peking Union Medical College Hospital(China).

    STAGE OF DEVELOPMENT:

    • GLP preclinical, analytical, stability and process development through 2019.  
    • Phase I trial in US beginning Spring 2020.
    • Phase II Trial planned Sep 2021

    PRINCIPAL COLLABORATORS: NIH & Memorial Sloan Kettering Medical Center

    IP: “Chemical Conjugates of Evans Blue Derivatives and their use as Radiotherapy and Imaging Agents (PCT/US2017/054863) filed October 3, 2017, pending

    FUNDING: Applied for Fast Track Phase 1 &2 SBIR. 

    OWNERSHIP: MTTI awarded world-wide-exclusive rights 

  • FGA (18F-Glucaric Acid)
    Cells with high metabolism actively consume D-Glucaric acid. 18F labeling sees acute MI, stroke and cancers. The 99mTc analog was safe and effective in 500 patient, Phase II trials, demonstrating clear, early visualization and fast clearance....

  • NAME: 18F Glucaric Acid

    CLASS: Imaging Agent

    INDICATIONS:  stroke (primary). 

    BACKGROUND:

    The 99mTc glucaric analog:

    • Demonstrated excellence in quickly, clearly imaging stroke and  MI.
    • Detects both primary and metastatic tumors sooner and more clearly than 18F FDG or 99mTc Sestamibi and is unaffected by breast density

    TECHNOLOGY: 

    D-Glucaric acid competes with fructose and glucose  for active uptake by cells with enhanced metabolism.  Labeling with 18F visualizes those cells,  detecting acute MI,  stroke and various cancers -breast, head-neck, lung (NSCLC, SCLC), carcinoma of the tongue.  The 99mTc analog was safe and effective in 500 patients through FDA approved, Phase II clinical trials.  It demonstrated fast blood clearance and  is highly avid for myocardial necrosis.

    UNMET NEED:   The 99mTc analog

    • Demonstrated excellence in quickly, clearly imaging stroke and  MI.
    • Detects both primary and metastatic tumors sooner and more clearly than 18F FDG, a $900million market,  and 99mTc Sestamibi.  It is not affected by breast density

    STAGE OF DEVELOPMENT: Preclinical Development

    PRINCIPAL COLLABORATOR: University of Oklahoma

    IP: Patent applied for

    OWNERSHIP: Shared equally with the University of Oklahoma with an exclusive, worldwide license to their technology.

  • TDURA (99mTc-Duramycin)
    Ending poor cancer therapy early cuts costs and patient stress. Current tools track tumor shrinkage or metabolic change weeks after treatment. TDURA sees tumor death, in vivo, directly, within days, quickly enabling alternative treatment....

  • NAME: TDURA

    CLASS: Imaging Agent

    INDICATION:  cancer, injury due to drug toxicity, atherosclerotic plaque and acute myocardial infarction

    USES: demonstrated in multiple preclinical studies visualizing:

    • Tumor response to chemotherapy
    • Systemic inflammatory response syndrome (SIRS)
    • Injury due to drug toxicity
    • Cardiac transplant rejection
    • Atherosclerotic plaque
    • Acute myocardial infarction

    TECHNOLOGY:  Cell death is the surrogate endpoint for most disease states and anticancer therapies (tumor death).  There is no direct cell death imaging agent yet accepted in routine clinical practice.

    TDURA, a small, peptide-based radiopharmaceutical imaging agent labeled with 99mTc, sees cell death, in vivo, directly and enables early, actionable efficacy tracking of tumor cell death within days of the first treatment. It has a unique mechanism of action, binds well to phosphatidylethanolamine markers on dying cells, and clears readily, a model imaging agent.

    UNMET NEED: 

    Lack of response to therapy is a major hurdle for cancer treatment. Early assessment of tumor response to therapy is critical.  Current methods to measure tumor response observe tumor shrinkage or metabolic changes, which may not be detectable for weeks. Ending ineffective therapy early minimizes costs and patient stress.

    Systemic inflammatory response syndrome (SIRS) is associated with pro- and anti-inflammatory cytokines in serum, including tumor necrosis factor (TNF). TNF has multiple effects and leads to cytokine production, leukocyte infiltration, blood pressure reduction and coagulation, thereby contributing tissue damage and organ failure. TDURA imaging can be used for whole body assessment of tissue damage during diseases associated with inflammation and injury.

    PROOF OF CONCEPT: 35 publications prove concept and demonstrate utility in multiple indications (see above) concentrated on visualizing tumor death in colorectal cancer.

    STAGE OF DEVELOPMENT: In Phase 0/1 clinical trials in Q4 2019. 

    PRINCIPAL COLLABORATOR: University of Antwerp MICA (Molecular Imaging Center Antwerp)

    IP: US 7,877,783 B2, US 8,778,303B2, Chinese patent CN102014970B, European approved 2017. These patents are secure through 2029 in US, EU and China. MTTI obtained an exclusive license from the Medical College of Wisconsin.

    FUNDING: ~$3 million non-dilutive grants from NIH & EU.

    OWNERSHIP: MTTI

For Technical Support with this webpage, please contact support.